Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high ...

The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections — was cited for having cat hair, pests, and bacteria, a recent FDA inspection showed.

Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

Wells Fargo analyst Yanan Zhu raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $82 from $77 and keeps an Overweight rating on the ...

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

The latest international Bageshri Banerjee news and views from Reuters - one of the world's largest news agencies ...

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema ...

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...